Table 1.
Basic characteristics of the patients with advanced NPC receiving concurrent chemoradiotherapy.
| Characteristic | Unmatched | Matched | ||||
|---|---|---|---|---|---|---|
| Weekly cisplatin No.(%) | 3-weekly cisplatin No.(%) |
P value | Weekly cisplatin No.(%) | 3-weekly cisplatin No.(%) |
P value | |
| Sex | 0.494 | 1.000 | ||||
| Male | 78 (68.4) | 92 (72.4) | 57 (63.6) | 57 (63.6) | ||
| Female | 36 (31.6) | 35 (27.6) | 33 (36.7) | 33 (36.7) | ||
| Age(years) | 0.358 | 0.724 | ||||
| Median | 45 | 44 | 46 | 41 | ||
| Range | 21-66 | 20-66 | 21-66 | 20-62 | ||
| T classification | 0.722 | 1.000 | ||||
| T1-2 | 23 (20.2) | 28 (22.0) | 19 (21.1) | 19 (21.1) | ||
| T3-4 | 91 (79.8) | 99 (78.0) | 71 (78.9) | 71 (78.9) | ||
| N classification | 0.154 | 1.000 | ||||
| N0-1 | 40 (35.1) | 56 (44.1) | 40 (44.4) | 40 (44.4) | ||
| N2-3 | 74 (64.9) | 71 (55.9) | 50 (55.6) | 50 (55.6) | ||
| Overall stage | 0.522 | 0.138 | ||||
| Ⅲ | 83 (72.8) | 100 (78.7) | 63 (70.0) | 74 (82.2) | ||
| ⅣA | 24 (21.1) | 22 (17.3) | 20 (22.2) | 13 (14.5) | ||
| ⅣB | 7 (6.1) | 5 (4) | 7 (7.8) | 3 (3.3) | ||
| WHO histological classification Type 2 | 0.242 | 0.494 | ||||
| Differentiated | 4 (3.5) | 10 (7.9) | 3 (3.3) | 6 (6.7) | ||
| Undifferentiated | 110 (96.5) | 117 (92.1) | 87 (96.7) | 84 (93.3) | ||
| KPS | 0.734 | 1.000 | ||||
| <90 | 30 (26.3) | 31 (24.4) | 22 (24.4) | 22 (24.4) | ||
| ≥90 | 84 (73.7) | 96 (75.6) | 68 (75.6) | 68 (75.6) | ||
| EBV DNA (copies/ml) | 0.225 | 0.450 | ||||
| <1000 | 69 (60.5) | 67 (52.8) | 50 (55.6) | 55 (61.1) | ||
| ≥1000 | 45 (39.5) | 60 (47.2) | 40 (44.4) | 35 (38.9) | ||
T and N categories are according to the 7th edition of the International Union Against Cancer/American Joint Commission on Cancer staging system.
Abbreviations: KPS, Karnofsky performance score; NPC, nasopharyngeal carcinoma.